Feb 16, 2017 - Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences

​​GS-6637 utilizes a novel pathway for the potential treatment of substance and behavior based addictions

Lou Lange, MD, PhD, Executive Chairman and Founder

  • General Partner Asset Management; Senior Advisor to CEO, Gilead Sciences
  • Former Founder Chairman & CEO, CV Therapeutics; Chief of Cardiology and Professor of Medicine at Jewish Hospital Washington University

William A. Lee, PhD

  • Executive Vice President Research, Gilead Sciences
  • Former leadership positions at California Biotechnology and Syntex Research

The Amygdala founders have deep and varied expertise in drug development and the addiction space. In addition to our individual experiences, we are all former members of the executive management team that built CV Therapeutics into a FIPCO and developed two first-in-class NCEs approved in the US and EU and achieved guideline status in both territories with current global revenues over $1.6B.

Ivan Diamond, MD, PhD, Chief Scientific Officer and Founder

  • Former Senior Advisor, Gilead Sciences; VP Neurology Research, CVT;  Vice Chair, UCSF Department of Neurology; Founding Director, UCSF Ernest Gallo Clinic and Research Center


Adrienne MacMillan, Chief Financial Officer and Founder

  • Former CFO, Rapidscan Pharma Solutions; VP Finance, CVT

Peter Strumph, President and Chief Executive Officer and Founder

  • Former SVP Operations, Portola Pharmaceuticals; CEO, Codexis; CEO, Nile Therapeutics; SVP Operations, CVT; Operations Planning, Biogen; Lieutenant, US Navy

The Board of Directors

ANS-6637 is in Clinical Development as a Treatment for Substance Use Disorder

ANS-6637 is the first-in-class compound that utilizes a novel pathway for the treatment of substance and behavior based addictions. ANS-6637, a highly selective ALDH2 Inhibitor with the potential to treat behavior and substance addictions based on a published mechanism of action in the brain that prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine. In published pre-clinical studies, ANS-6637 reduced alcohol, cocaine and opiate craving in cue-induced models of addiction and demonstrated anxiolytic properties in models of stress. ANS-6637 has been studied in over 100 human subjects.

In addition to Lou Lange (Executive Chairman), Ivan Diamond, and Peter Strumph, the BOD includes:

Aug 1, 2017 - Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder

Mack Mitchell, MD

  • UT SW Internal Med Vice-chair; Former Hopkins Chief of Gastroenterology
  • President, The Foundation for Alcohol Research (ABMRF)

A Biopharmaceutical Company Focused on the Development and Commercialization of First-In-Class Drug Candidates for Addiction Disorders